Buscopan
Phase 1Small molecule
Boehringer IngelheimBuscopan is one of 38 small molecule programs targeting Renal Colic. It is currently in Phase 1.
1
Indications
4
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Renal Colic
#DrugCompanyPhaseTrials
1MS Contin
HHikma Pharmaceuticals LLC
Approved
Duragesic
CCephalon
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Keterol
PPamukkale University
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Paracetamol
GSKApproved
Demerol
QQuagen
Approved
Suboxone
IIndivior Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy2 trials
Gastrointestinal1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Buscopan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company